Here's Why Shares in Aehr Test Systems Declined in December, But Looks a Great Buy Now

Aehr Test Systems reported shrinking revenue and a small non‑GAAP loss even as AI‑related orders accelerate: revenue fell to $20.9 million in the first six months versus $26.6 million a year earlier and a non‑GAAP loss of $0.4 million was reported. Shares dropped 12.1% in December amid investor rotation away from riskier AI plays, but management says backlog rose from $11.8 million (Nov. 28) to $18.3 million and expects second‑half bookings of $60–$80 million, which would position the company for a stronger fiscal 2027 beginning May 30, 2026. The stock therefore presents a recovery/turnaround narrative tied to AI processor WLBI demand while legacy EV/SiC test revenue remains under pressure.

Analysis

Market Structure: Aehr (AEHR) sits at the intersection of two demand pools — EV SiC WLBI (currently soft) and AI processor WLBI (ramp). The recent backlog jump from $11.8M to $18.3M and management’s H2 bookings target of $60–80M imply a potential shift in revenue mix toward hyperscalers; a converted $60M booking set would likely double+ FY revenue given current run-rate. Limited peer supply for WLBI gives Aehr selective pricing power if it can scale, but EV OEM capex cyclicality keeps overall demand uncertain. Cross-asset: heightened equity volatility and wider credit spreads for small-cap semicap names are likely; options IV will remain rich around earnings and booking updates, while EV commodity exposure (copper, SiC precursor materials) tracks longer-term EV recovery rather than Aehr-specific moves.

Risk Assessment: Key tail risks are loss of the hyperscaler as a concentrated customer, forward booking non-conversion, and execution/capacity build delays leading to >25% downside from here. Immediate (days) risk is sentiment-driven 10–30% swings; short-term (weeks–months) hinges on quarterly booking updates and cash burn; long-term (12–24 months) depends on EV capex resumption and multi-customer WLBI adoption. Hidden dependencies include margin profile differences between AI and EV WLBI orders, supplier lead times for test sockets, and potential covenant/dilution if cash runway <12 months. Catalysts: monthly/backlog disclosures, FY2027 guidance cadence (May 30, 2026 start), and hyperscaler repeat orders.

Trade Implications: Direct play — establish a small, tactical long in AEHR sized 2–3% of portfolio beta-to-equities to capture upside if bookings convert; use tight risk rules (stop if backlog < $25M by May 30, 2026). Options — prefer long-dated Jan 2027 LEAP calls (12–18 months) or buy-call spreads to cap premium; allocate no more than 1% notional to LEAPs. Pair trade — long AEHR (2%) vs short a diversified large-cap AI beneficiary basket (e.g., partial short exposure to ORCL index weight 1%) to hedge broad AI sentiment roll-off. Sector rotation — trim cyclical EV supply chain exposure by 20–30% in favor of select semiconductor test/equipment names.

Contrarian Angles: Consensus may be underrating conversion probability of bookings and the strategic value of a hyperscaler customer; if management converts to >$60M bookings and shows multi-customer traction, re-rating could be ≥2–3x within 12–18 months. Conversely, the market may be underpricing dilution/execution risk — a failed conversion or equity raise would compress equity >50%. Historical parallel: small capital equipment providers (test/pack) have doubled when landing multi-year hyperscaler programs but also gone to zero with single-customer failures; therefore position sizing and explicit booking thresholds are critical to avoid asymmetric downside.

Key Decisions for Investors

• Establish a tactical long in AEHR equal to 2–3% of portfolio notional now; set a stop-loss to exit if company backlog fails to exceed $25M by May 30, 2026, or if the company announces a dilutive equity raise that increases shares outstanding by >10%.
• Buy Jan 2027 AEHR LEAP calls (12–18 month tenor), size to 1% of portfolio notional (prefer call spread to cap premium), and plan to roll or exercise if bookings convert to ≥$60M supporting FY2027 revenue acceleration.
• Enter a pair trade: long AEHR (2% portfolio) vs short ORCL-equivalent exposure (1% portfolio) or a 3–5 stock basket of large, profitable AI services beneficiaries; rationale is to capture idiosyncratic re-rating if AEHR converts bookings while hedging macro AI sentiment risk.
• Reduce cyclical EV supply-chain exposure by 20–30% over next 60 days and redeploy proceeds into semicap test/equipment names and AEHR if monthly booking updates are positive; if backlog reaches management’s low-end target of $60M by May 30, 2026, increase AEHR allocation to 4–5%.
• Monitor three high‑impact triggers over the next 6 months: monthly backlog updates (convert to revenue within 6–12 months), cash runway (announce no need to raise capital within 12 months), and any hyperscaler contract renewal/expansion; if two of three fail, exit AEHR positions immediately.